Young patients diagnosed with systemic lupus erythematosus (SLE) show a high number of visits to healthcare facilities in the year before their diagnosis, research shows. The study, “High Health Care Utilization Preceding Diagnosis of Systemic Lupus Erythematosus in Youth,” was published in the journal Arthritis Care & Research. While advances…
Corbus Pharmaceuticals has obtained a U.S. patent for the way that its therapy anabasum works to combat lupus, systemic sclerosis, cystic fibrosis and other inflammatory diseases. The protection that the U.S. Patent and Trademark Office granted Corbus for the therapeutic process that anabasum uses will run through 2034. Anabasum is a synthetic…
Patients with systemic lupus erythematosus (SLE) show significantly higher rates for dementia compared to healthy people, according to a large cross-sectional Israeli study. The research, “High proportions of dementia among SLE patients: A big data analysis,” was published in the journal International Journal of Geriatric Psychiatry. Lupus…
Women with systemic lupus erythematosus (SLE) in the U.S. live on average 22 years less — and men an average of 12 fewer years — than members of the same sex among the public at large, according to new data from Stanford University. Leading causes of death for female…
GlaxoSmithKline’s Benlysta reduced lupus patients’ need for higher doses of corticosteroids, a therapy that is beneficial but causes long-term organ damage, an additional analysis of Phase 3 clinical trial results shows. In addition, a combination of Benlysta and corticosteroids reduced patients’ organ damage more than corticosteroids alone over five years, two extensions…
Obese women with systemic lupus erythematosus (SLE) have a poorer quality of life and suffer more symptoms than women of normal weight, according to new research presented at the 2017 ACR/ARHP Annual Meeting in San Diego. The study, “Obesity Independently Associates with Worse Patient Reported Outcomes in Women with Systemic…
Janssen announced that its investigational antibody Stelara (ustekinumab) showed positive results in a Phase 2 trial as a therapy for patients with systemic lupus erythematosus (SLE). Based on these results, the company said it would further test Stelara in a Phase 3 development program planned for 2018. The study, “Efficacy and…
Nimbus Therapeutics, which uses computer analysis to identify and develop therapies for autoimmune diseases like lupus, has established a long-term strategic alliance with Celgene, a company that focuses on immunology. The agreement promises to foster the development of new therapies for diseases triggered by imbalanced immune system responses. Nimbus…
Patients with systemic lupus erythematosus (SLE) report high levels of satisfaction when Benlysta (belimumab) therapy was self-administered using an autoinjector, a small study reports. The study, “Patient Evaluation of Satisfaction and Outcomes with an Autoinjector for Self-Administration of Subcutaneous Belimumab in Patients with Systemic Lupus Erythematosus,” was published in…
Certain autoantibodies may help identify the small group of patients with systemic lupus erythematosus (SLE) at risk of developing pulmonary arterial hypertension (PAH), and those who are at lower risk of death, according to the findings of a retrospective French study. The research, “Pulmonary Arterial Hypertension Associated…